Litcius/Paper detail

Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child

Yohei Yamaguchi, Kei Takasawa, Hitoshi Irabu, Kanako Hiratoko, Yosuke Ichigi, Ko Hirata, Yumie Tamura, Miki Murakoshi, Motoi Yamashita, Hisae Nakatani, Masuhiro Shimoda, Taku Ishii, Tomohiro Udagawa, Masaki Shimizu, Hirokazu Kanegane, Tomohiro Morio

2022Journal of Infection and Chemotherapy19 citationsDOIOpen Access PDF

Topics & Concepts

MedicineInfliximabRefractory (planetary science)Incidence (geometry)Internal medicineAspirinPrednisoloneGastroenterologyPathogenesisImmunologyTumor necrosis factor alphaPhysicsOpticsAstrobiologyKawasaki Disease and Coronary ComplicationsAutoimmune and Inflammatory Disorders ResearchStreptococcal Infections and Treatments
Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child | Litcius